Physiologic Plasticity of Intramyocardial Lipid Storage

August 8, 2013 updated by: University Hospital Inselspital, Berne

Patterns and Plasticity of Orthotopic and Ectopic Fat Deposition and Associations With Insulin Sensitivity: A Magnetic-resonance-imaging and -Spectroscopy Study in Lean and Obese Individuals: Methodological Part

The main goal of the present study was to provide a technical basis for future studies assessing the role of cardiac lipids. More specifically, non-invasive MR-Spectroscopy (MRS) techniques will be used in this study to:

  1. assess the methodological reproducibility of MRS-measurements of cardiac lipids in humans
  2. investigate physiological variations of cardiac lipids by measuring day-to-day changes under identical conditions
  3. determining diurnal variations of cardiac lipids in humans

Study Overview

Detailed Description

Background

Obesity is a well known risk factor for the development of glucose intolerance, type 2 diabetes mellitus and, consequently, diabetic complications like cardiovascular disease. Importantly, obesity is not only associated with lipid accumulation in adipose tissue (orthotopic fat deposition), but also in non-adipose tissues (ectopic fat deposition). Clinical studies have repetitively shown that muscular and hepatic lipid accumulation as well as elevated visceral adipose tissue is associated with the development of central and peripheral insulin resistance. In addition, recent data from animal studies show increasing evidence that two other organs, the heart and the pancreas, may also be involved in the pathophysiological processes of reduced insulin sensitivity. While reduced insulin secretion in the course of type 2 diabetes has been well documented, the importance of pancreatic fat deposition as an early step in this process has only recently been suggested based on animal models. Conversely, ischemic heart disease is one of the most dangerous complications of diabetes mellitus, its prevention thereby being a cornerstone of current diabetes management. Recent data suggest that changes in the lipid metabolism of the heart and associated epi- and myocardial lipid deposition may be earliest signs of diabetic cardiopathy.

Magnetic-Resonance-Imaging (MRI) and -Spectroscopy (MRS) are among the most versatile methods for non-invasive studies of human tissue and/or metabolism in vivo and in situ. The excellent soft tissue contrast of MRI has already led to the implementation of this method for the assessment of whole body lipid accumulation, whereas MRS has successfully been applied to study lipid metabolism of skeletal muscle and liver. The extended application of this method towards heart and pancreas will allow a comprehensive investigation of orthotopic and ectopic fat deposition in humans and its association with the development of insulin resistance and diabetes mellitus.

The methodological part of the study will focus on the physiologic plasticity of cardiac lipids in order to assess:

i) methodological reproducibility ii) intra-individual physiological reproducibility by measuring day-to-day variations as well as variations during the day.

Objective

i) Adapting and optimizing the single-voxel MRS sequence that is currently used for muscle and liver, such that respiratory and cardiac double-triggering enables spectroscopy of the cardiac muscle.

ii) Validate the methodology under different standardized physiologic conditions.

Methods

Cardiac lipids are determined during five independent MR-examinations distributed over two days separated by one or two weeks. Both days included a measurement in the morning after an overnight fast (>8h) and one in the afternoon (8h after breakfast, 3.5h after lunch). To determine methodological reproducibility, the afternoon measurement was repeated on one of the two days (1h break). Preparation of the volunteers included perpetuation of their normal diet, but restricted physical activity for two preceding days. Cardiac lipids were determined by single-voxel MR-Spectroscopy.

Study Type

Observational

Enrollment (Actual)

9

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bern, Switzerland, CH-3010
        • Institute of Diagnostic Interventional and Pediatric Radiology, University Hospital Bern

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

males between the age of 18 and 30 years with either a BMI of 18-24

Description

Inclusion Criteria:

  • male
  • age 18-30
  • BMI <25
  • healthy
  • written informed consent

Exclusion Criteria:

  • contraindications to MRI examinations (claustrophobia, implanted devices (pacemaker, insulin pump, neurostimulators))

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Volunteers
young (age<30), healthy, lean (BMI<25) volunteers
normal dietary behavior during examination days
Non-invasive diagnostic procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Intramyocardial lipid content
Time Frame: at baseline (morning of examination day 1)
at baseline (morning of examination day 1)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intramyocardial lipid content
Time Frame: evening of examination day 1, i.e. 8 hours after baseline
evening of examination day 1, i.e. 8 hours after baseline
Intramyocardial lipid content
Time Frame: morning of examination day 2, i.e. 7 days after baseline
morning of examination day 2, i.e. 7 days after baseline
Intramyocardial lipid content
Time Frame: evening of examination day 2, i.e. 7 days & 8 hours after baseline
evening of examination day 2, i.e. 7 days & 8 hours after baseline
Intra-individual variation of intramyocardial lipid content
Time Frame: evening of examination day one, i.e. 8 hours after baseline
Difference between evening and morning measurement within examination day one
evening of examination day one, i.e. 8 hours after baseline
Intra-individual variation of intramyocardial lipid content
Time Frame: evening of examination day two, i.e. 7 days & 8 hours after baseline
Difference between evening and morning measurement within examination day two
evening of examination day two, i.e. 7 days & 8 hours after baseline
Intra-individual difference of intramyocardial lipid content (morning) over one week
Time Frame: morning of examination day one, i.e. 7 days after baseline
Difference between morning measurements of examination day 1 and examination day 2
morning of examination day one, i.e. 7 days after baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Ith, PhD & MD/PhD, University Institute of Diagnostic Interventional and Pediatric Radiology of the Inselspital Bern

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (ACTUAL)

December 1, 2011

Study Completion (ACTUAL)

December 1, 2011

Study Registration Dates

First Submitted

August 5, 2013

First Submitted That Met QC Criteria

August 8, 2013

First Posted (ESTIMATE)

August 13, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

August 13, 2013

Last Update Submitted That Met QC Criteria

August 8, 2013

Last Verified

August 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • 124/08
  • 1587 (OTHER: Inselspital)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lipid Metabolism

Clinical Trials on normal dietary behavior

Subscribe